{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073456","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.769970+00:00","generated_at":"2026-05-15T23:39:29.931829+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intellia Q4 net loss $95.8M; lonvo-z Phase 3 data mid-2026; nex-z clinical hold remains for ATTR-CM","bullets":["Q4 2025 net loss $95.8M vs $128.9M Q4 2024; cash $605.1M, expected to fund operations into H2 2027.","Lonvo-z (HAE): HAELO Phase 3 topline data by mid-2026; BLA submission H2 2026; U.S. launch anticipated H1 2027.","Nex-z (ATTR): MAGNITUDE-2 enrollment restart underway, completion expected H2 2026; MAGNITUDE clinical hold on ATTR-CM unresolved.","Market research: 99% of HAE patients likely to take lonvo-z; 92% of physicians would prescribe.","R&D expenses $88.7M (down from $116.9M); collaboration revenue $23.0M (up from $12.9M) including $9.0M from SparingVision termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073456","json":"https://secwatch.observer/filing/0001193125-26-073456.json","markdown":"https://secwatch.observer/filing/0001193125-26-073456.md","text":"https://secwatch.observer/filing/0001193125-26-073456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526073456/0001193125-26-073456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526073456/ntla-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:39:29.931829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}